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The Journal of Immunology
Functional Analysis of a Complement Polymorphism
(rs17611) Associated with Rheumatoid Arthritis
Joanna L. Giles,* Ernest Choy,† Carmen van den Berg,‡ B. Paul Morgan,*,1 and
Claire L. Harris*,1
Complement is implicated in the pathogenesis of rheumatoid arthritis (RA); elevated levels of complement activation products have
been measured in plasma, synovial fluid, and synovial tissues of patients. Complement polymorphisms are associated with RA in
genome-wide association studies. Coding-region polymorphisms may directly impact protein activity; indeed, we have shown that
complement polymorphisms affecting a single amino acid change cause subtle changes in individual component function that in
combination have dramatic effects on complement activity and disease risk. In this study, we explore the functional consequences of
a single nucleotide polymorphism (SNP) (rs17611) encoding a V802I polymorphism in C5 and propose a mechanism for its link to
RApathology. Plasma levels of C5, C5a, and terminal complement complex weremeasured in healthy andRA donors and correlated
to rs17611 polymorphic status. Impact of the SNP on C5 functionality was assessed. Plasma C5a levels were significantly increased
and C5 levels significantly lower with higher copy number of the RA risk allele for rs17611, suggesting increased turnover of C5
V802. Functional assays using purified C5 variants revealed no significant differences in lytic activity, suggesting that increased C5
V802 turnover was not mediated by complement convertase enzymes. C5 is also cleaved in vivo by proteases; the C5 V802 variant
was more sensitive to cleavage with elastase and the “C5a” generated was biologically active. We hypothesize that this SNP in C5
alters the rate at which elastase generates active C5a in rheumatoid joints, hence recruiting neutrophils to the site thus main-
taining a state of inflammation in arthritic joints. The Journal of Immunology, 2015, 194: 3029–3034.
R
heumatoid arthritis (RA) is a chronic inflammatory dis-
ease affecting almost 1% of the population worldwide (1).
RA susceptibility involves a combination of genetic
factors and environmental triggers such as infection and smoking
(2). Genome-wide association studies identified multiple genetic
links to RA (3–6); several implicated the TNFR-associated factor
(TRAF)1/complement C5 region as a susceptibility locus.
Complement is a key component of innate immunity with roles
in protecting against infection and linking innate and adaptive
immune responses. Complement is a proteolytic cascade com-
prising more than 30 proteins; the activation pathways (classical,
alternative, and lectin) involve sequential events, generating new
enzymes and active fragments (7–9). Cleavage of C3 generates
anaphylactic (C3a) and opsonic (C3b) fragments. Subsequent
cleavage of C5 yields the anaphylactic fragment C5a and C5b
which initiates assembly of the lytic membrane attack complex.
There are strong links between the pathogenesis of RA and the
complement system (10). Complement activation fragments are
elevated in plasma and synovial fluid in patients (11, 12), and
complement activation products are found in joint tissues leading
to the suggestion that joint damage is in part mediated by com-
plement (13). Evidence from experimental models also implicates
complement in RA; anti-C5 Ab ameliorated disease in mouse
collagen-induced arthritis in mice-ameliorated disease (14, 15),
and C5-deficient mice were refractory to collagen-induced ar-
thritis (16).
Complement polymorphisms influence risk in many diseases
(17); small differences in activities of polymorphic variants, when
inherited in some combinations (the complotype), dramatically alter
complement activity and impact disease risk (17, 18). TRAF1/C5
is a highly polymorphic locus on chromosome 9 linked to RA
susceptibility (19, 20). Many of the susceptibility single nucleo-
tide polymorphisms (SNPs) are in linkage disequilibrium with
each other. We focused on a coding SNP in this locus linked to
RA in multiple studies, rs17611, a miss-sense polymorphism
causing a V802I change in C5 (4, 20). The SNP is also linked to
periodontitis (21), poor outcome in pneumococcal meningitis
(22), adverse cardiovascular outcomes (23), and stroke risk (24).
No functional basis for these disease associations has been
described.
In this study, we show that individuals homozygously expressing
the RA risk s17611 allele exhibit increased C5a and decreased C5
in plasma, evidence of increased C5 turnover. We demonstrate that
C5V802I variants are indistinguishable in complement activation
assays; however, the risk C5V802 variant is more susceptible to
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cleavage by human neutrophil elastase (HNE), generating an ac-
tive fragment functionally indistinguishable from C5a. We suggest
that increased susceptibility to cleavage by HNE, with release of
proinflammatory fragments, explains the association of the poly-
morphism with RA and other inflammatory diseases in which
elastase levels are locally elevated.
Materials and Methods
DNA preparation and genotyping
Blood was collected into EDTA from healthy donors and from RA and
osteoarthritis patients satisfying American College of Rheumatology/
European League Against Rheumatism classification criteria (25). An al-
iquot was used for gDNA preparation and plasma harvested from the re-
sidual stored at 280˚C. gDNAwas purified using a RELIAprep gDNA kit
(Promega, Southampton, U.K.) following manufacturer’s instructions.
gDNA concentration was determined using a Nanodrop 1000 spectro-
photometer (Thermofisher, Loughborough, U.K.). All samples were nor-
malized to 10 ng/ml and genotyped at the rs17611 SNP using Kaspar
technology (Kbiosciences, Teddington, U.K.).
Measurement of complement components
C5, C5a, C3a, and the terminal complement complex (TCC) were measured
in EDTA plasma from genotyped donors. C5a and C3awere measured using
commercial ELISA kits (Microvue; Quidel, San Diego, CA), according to
the manufacturer’s instructions. TCC levels were measured in an in-house
ELISA. Briefly, 96-well Maxisorp plates (Thermofisher) were coated with
anti-TCC Ab (aE11, Hycult, The Netherlands) at 2 mg/ml in carbonate/
bicarbonate buffer (pH 9.6); plates were blocked in 2% BSA and then
incubated with plasma samples. Detection was with HRP-conjugated anti-
C8 mAb (clone E2) in 2% BSA and color developed using orthopheny-
lenediamine (Sigma-Aldrich, Dorset, U.K.). Plasma C5 levels were mea-
sured using a novel in-house C5 ELISA. Briefly, 96-well Maxisorp plates
were coated with an in-house polyclonal rabbit anti-human C5 Ab (8 mg/ml
IgG in bicarbonate buffer [pH 9.6]), blocked in 2% BSA, and then incubated
with plasma samples diluted 1 in 600 in 2% BSA. Bound C5 was detected
using a mouse monoclonal anti-human C5 (MBI-C5-3; developed in-house,
5 mg/ml), followed by donkey anti-mouse IgG HRP (Jackson Labs, Stratech,
Newmarket, U.K.; 1 in 2500) and color developed using orthophenylenedi-
amine. Plasma levels of complement components were calculated using
Graphpad prism 3 (GraphPad, La Jolla, CA), and statistical analysis was
performed using one-way ANOVA. For C5, p = 0.0047; for C5a, p, 0.0001;
and for TCC, p = 0.6032.
C5 purification
Donors homozygous for the C5V802I polymorphic variants were identified
and EDTA plasma collected. C5 was purified by affinity chromatography
on monoclonal anti-human C5 (MBI-C5-2; 30 mg) immobilized to a 5 ml
HiTrap column (GE Healthcare, Fisher Scientific, Loughborough, UK.). on
an Akta Purifier system (GE Healthcare). Plasma (50 ml) was loaded onto
the column which was then washed in HEPES buffered saline (HBS;
10 mM HEPES and 150 mM NaCl [pH 7.4]; 10-column volumes) and
eluted using 2 M MgCl2 in HBS. The C5 peak was collected, loaded
immediately onto a SD200 gel filtration column (GE Healthcare), and
eluted in HBS to remove aggregates and desalt. Purity was confirmed by
SDS PAGE and protein concentration measured using the Bradford assay
(Bio-Rad) and Nanodrop.
Add-back hemolytic assays
Functional differences between the two C5 variants were probed using add-
back hemolytic assays. C5 was depleted from normal human serum (NHS) by
passage over the C5 affinity column equilibrated in ice-cold HBS. Ab-
sensitized sheep erythrocytes (ShEA) were prepared using standard proto-
cols (26). C5 was titrated as indicated in 50 ml complement fixation diluent
(CFD; Sigma-Aldrich) in a 96-well plate; 50 ml ShEA in CFD was added to
the wells, and lysis was developed by adding 50 ml C5-depleted serum di-
luted 1 in 5 in CFD. To measure rate of lysis, plates were incubated in a 37˚C
chamber of an Anthos ht3 plate reader (LBMG Labtech, Aylesbury, U.K.),
where residual intact cells were measured densitometrically by reading A690
at 3-min intervals for 30 min. The percentage of intact cells was calculated at
each time point using the Equation 100*(A690 test sample 2 A690 100%
control)/(A690 0% control 2 A690 100% control), and rate of lysis plotted
using Graphpad prism 3. To calculate end-point lysis, plates were incubated
at 37˚C for a set time, cells were pelleted by centrifugation, and hemoglobin
release was measured by absorbance at 415 nm. Control incubations in-
cluded 0% lysis (buffer only) and 100% lysis (0.1% Nonidet-P40). Per-
centage lysis (100 3 [A415 test sample 2 A415 0% control]/[A415 100%
control 2 A415 0% control]) was calculated.
C5 convertase/terminal pathway hemolysis assays
ShEA-C3b intermediates were generated by incubating ShEA with NHS
depleted of factor B and factor H (NHSDBH) (27); cells were washed,
resuspended to 2% in alternative pathway buffer (veronal-buffered saline
containing 7 mM MgCl2 and 10 mM EGTA). To form C5 convertase,
ShEA-C3b were washed, resuspended in alternative pathway buffer, and
incubated with factor B [4.09 mg/ml; in-house (28)] and factor D (0.25 mg/
ml; Comptech) for 15 min at 37˚C. C5 convertase–coated cells were im-
mediately added to titrated doses of C5 and constant C6 (physiological
concentration of 65 mg/ml) and incubated (37˚C, 10 min) in a 96-well
plate. Lysis was developed by adding C7, C8, and C9 (all purified in house;
55, 55, and 60 mg/ml respectively). Rate of lysis and end-point lysis were
measured as described above.
Cobra venom factor assays
Cobra venom factor (CVF) was purified from lyophilised Naja naja kaouthia
venom (Sigma-Aldrich). Briefly, 200 mg lyophilized venom was solubilized in
10 ml TBS (pH 8.5). Insoluble material was removed by centrifugation, and
filtered supernatant was applied to a DEAE sepharose column at 4˚C on an
Akta Purifier. CVF was eluted using a linear gradient to 1 M NaCl in TBS.
Fractions were screened on 7.5% SDS-PAGE gels. Fractions corresponding to
CVF were dialyzed into PBS (10 mM phosphate and 150mM NaCl [pH 7.5])
and applied to a SD200 gel filtration column in PBS.
C5 convertase (CVFBb) was prepared by incubating 10 mg CVF, 10 mg
factor B, 0.12 mg factor D, and 5 mM MgCl2 in 50 ml TBS for 1 h at 37˚C
as described previously (29). Each C5 variant (30mg) was incubated with
8 ml of the preformed convertase at 37˚C. Aliquots (5 mg protein in a 5-ml
volume) were removed from the mix at intervals into an equal volume
of SDS reducing loading buffer. Samples were run on an 8.5% gel and
visualized by Coomassie staining using standard protocols. Band densi-
tometry was measured using ImageJ (http://rsb.info.nih.gov/ij/).
Enzyme cleavage assays
Each C5 variant (10 mg) was incubated with 0.5 mg HNE (Sigma-Aldrich)
in HBS buffer at 37˚C. Aliquots were withdrawn at intervals into SDS
loading buffer (6DTT) and heated at 100˚C for 5 min before running on
a 4–12% SDS gradient gel (Invitrogen), stained with Coomassie blue. C5a
was detected in HNE digests by Western blot; proteins were transferred
from SDS-PAGE to nitrocellulose then probed with anti-C5a (mAb557,
Hycult). C5a release was also measured using a C5a ELISA kit as de-
scribed above (Quidell).
Calcium Flux assays
U937 cells, stably transfected with the C5aR1 or IL-8RB (a gift from
E. Prossnitz, Albuquerque, NM) at 107cells/ml were loaded with 2 mM Fura-2-
AM for 30 min at room temperature. Cells were washed and resuspended in
Krebs/HEPES/BSA buffer (25 mM HEPES, 120 mM NaCl, 4.8 mM KCl, 1.2
mM KH2PO4, 1.2 mM MgSO4, 1.3 mM CaCl2 [pH 7.4], and 0.1% BSA).
Cells (200 ml at 53 106/ml) were stimulated with C5a, C5, or C5 preincubated
with HNE (2 h at 37˚C as described above). Changes in intracellular calcium
were measured as described previously (30, 31). To confirm that the observed
signal was C5a induced, a C5aR1 antagonist peptide (H-Phe-Lys-Pro-
D-Cha-Trp-D-Arg-OH) (100 nM diluted in Krebs/HEPES/BSA) was added
to the cells 10 min before stimulation with C5-derived cleavage products.
Results
Measurement of C5 and C5 activation products in plasma
samples
In 111 healthy donors genotyped for the rs17611 SNP, the minor
allele frequency was 0.46, in line with published frequency (Na-
tional Center for Biotechnology Information reported minor allele
frequency 0.41). Plasma levels of C5a, C5, and TCC were mea-
sured in the cohort; mean levels of these analytes were comparable
to published levels: [C5a] = 9.23 ng/ml, [C5] = 86.1 mg/ml, and
[TCC] = 0.31 mg/ml. When the cohort was divided on the basis of
rs17611 SNP status, risk allele number was positively associated
with [C5a] (p, 0.001 by ANOVA) and negatively associated with
[C5] (p = 0.005) (Fig. 1). Plasma [TCC] was not significantly
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different between the groups. Attempts to detect C5a in patient
and control plasma by Western blotting were unsuccessful, likely
because of its very low concentration. Synovial fluid was not
available from patients in the cohorts studied.
In a second cohort comprising 80 RA patients, [C5a] again
showed strong positive correlation with risk allele number (p ,
0.001), and [C5] showed a trend to negative correlation that did
not reach significance; as in healthy subjects (Supplemental Fig. 1),
[TCC] was not different between the groups (data not shown).
To assess whether the observed differences in C5 and C5a
concentrations were a result of systemic complement activation,
C3a levels were measured in 71 RA patients. There was no sig-
nificant difference between the groups (Supplemental Fig. 1),
leading us to conclude that the increased C5 turnover in risk allele
carriers was not due to increased complement activation.
Complement lytic activity of the two C5 V802I protein variants
To determine whether the decreased C5 and elevated C5a levels in
individuals expressing rs17611 risk alleles was the result of higher
turnover by the C5 convertase enzyme, hemolytic assays were
performed. C5 purified from healthy individuals homozygous for
each variant (C5V802 or C5I802) was titrated back into NHS de-
pleted of C5 (NHSDC5) and used in hemolysis assays. Neither end
point nor rate hemolytic assays showed any significant difference
between the C5 variants (Fig. 2).
To increase the sensitivity of this assay and reveal small dif-
ferences in C5 function, C3/C5 convertase coated sheep erythro-
cytes were generated and C5 variant proteins were titrated into the
cells. Lysis was developed by addition of purified terminal com-
ponents. No significant difference in the development of lysis was
seen between the two C5 variants (Fig. 3).
Finally, we compared the C5 variants in a CVF C3/C5 convertase
assay; no significant difference in rate or extent of cleavage of
the variants was observed, either by SDS-PAGE or by C5a ELISA
(Supplemental Fig. 2).
These data confirm that the C5V802I variants are not differen-
tially processed by the C5 convertase and provoked us to look for
alternative explanations for differences in turnover.
HNE cleaves C5V802I variants at different rates to produce an
active C5a-like fragment
HNE, an enzyme released from activated neutrophils at inflam-
matory sites, has been shown to cleave C5 (32), but the resulting
fragments have not been fully characterized. To assess the impact
of the C5V802I polymorphism on HNE-mediated cleavage, purified
C5 variants were digested with HNE. Cleavage of the C5 chains
was assessed on SDS-PAGE and appearance of the C5a-like frag-
ment measured by Western blotting with a C5a-specific mAb
(Fig. 4A). Both rate of disappearance of intact C5 and appearance
of the C5a-like fragment were greater for the C5 risk variant
C5V802. To confirm this accelerated cleavage, generation of the
C5a-like fragment was measured by ELISA; levels were higher
for C5V802 at all time points in the experiment, up to 6-fold at
60 min (Fig. 4B).
The HNE-generated C5a-like fragment migrated at a slightly
higher molecular mass compared with recombinant C5a and C5a
FIGURE 1. C5 and C5 activation products in plasma samples correlate to rs17611 genotype. (A) Genotyping a healthy population for rs17611. The gene
frequency of the risk allele (g) in this population is 0.54. (B) and (C), respectively, show C5a and C5 plasma levels in genotyped individuals measured by
ELISA. Plasma levels were observed to be significantly different with increasing copy number the risk variant (g) correlating to higher levels of C5a
(***p , 0.001) and lower levels of C5 (**p 5 0.05). (D) TCC plasma levels were also measured by ELISA and show no significant trend with genotype in
these assays.
The Journal of Immunology 3031











generated through cleavage of C5 by the CVFBb convertase, as
shown by Western blot with a C5a-specific mAb (Supplemental
Fig. 3). To test whether this HNE-generated fragment retained
C5a activities, C5 was incubated with or without HNE for 2 h
and then added to C5aR1-transfected U937 cells preloaded with
Fura2-AM. HNE-digested C5 triggered a prompt Ca2+ flux,
whereas addition of uncleaved C5 or HNE alone had no effect.
As a negative control, U937 cells transfected with an IL-8R did
FIGURE 2. Both C5 V802I variants show comparable complement lytic activity in standard hemolysis assays. (A) Two C5 variants were purified by
affinity chromatography and subsequent gel filtration. C5 variants were run on a reduced gel to confirm purity. Two bands were present, representing C5 a
(115 kDa) and C5 b (75 kDa). (B) C5 variants were titrated into C5-depleted serum and ShEA. C6–C9 was then added, and RBC lysis was measured by
hemoglobin release after 30-min incubation. Representative results from three experiments are shown. (C) The rate of lysis was calculated by measuring the
number of intact cells present at 3-min intervals at each concentration of C5 for the C5 add-back assays described. Results were calculated for each
concentration in of C5 in (B). The rate curves for two concentrations of C5 are shown. Representative results from three experiments are shown.
FIGURE 3. Both C5 V802I variants show
comparable complement lytic activity. (A) He-
molysis was measured by first coating sheep
erythrocytes with C3bBb and then titrating C5
and inducing lysis by adding remaining com-
plement components. The end-point assay is
shown after 30-min incubation. Percentage lysis
was calculated by measuring hemoglobin re-
lease for each C5 concentration at end point.
Representative results from more than six
experiments are shown. (B) The rate of lysis
was plotted by measuring absorbance of intact
cells at 3-min intervals for each concentration
of the C5 add back assays described. Two
representative concentrations of C5 are shown.
Representative results from six experiments are
shown.
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not respond to HNE-digested C5 (data not shown). Pre-
incubation with a C5aR1 antagonist blocked the HNE treated
C5-triggered increase in intracellular Ca2+ (Fig. 5). rC5a caused
a Ca2+ flux in C5aR1 expressing U937 comparable to that
caused by HNE-digested C5 (Fig. 5).
Discussion
Complement is a key component of the innate immune response,
and complement polymorphisms and mutations influence risk in
a range of diseases (17). Some complement polymorphisms have
been shown to influence complement activity, and the complotype
describes the inherited set of complement variants that dictate
complement function in an individual (18). Several polymorphisms
in C5 have been associated with RA in various populations (4, 20).
Multiple SNPs at the C5-TRAF locus have a significant association
(e.g., rs3761847 is the most significant with p = 2 3 1028), and
many of these are in linkage disequilibrium, making it difficult to
ascribe causality (20). In this paper, we report that the RA risk
allele of a coding SNP in C5 (rs17611) is associated with in-
creased C5 turnover and elevated plasma levels of the potent
anaphylatoxin C5a in healthy donors and RA patients. TCC levels
did not reflect this difference, likely because of the known inef-
ficiency of TCC generation in the fluid phase (33, 34). C3a levels
did not correlate with RA risk allele, suggesting that increased C5
turnover and C5a production occurred independently of down-
stream complement activation.
To investigate the cause of these differences, functional assays
comparing the C5V802I variants were performed. In multiple hemo-
lytic assays, no differences between the C5 variants was observed,
indicating that increased turnover of C5V802 was not caused by in-
creased susceptibility to cleavage by C5 convertase. These findings
eliminate the possibility that increased C5 turnover in normal indi-
viduals expressing the risk variant is due to increased complement
enzyme cleavage during tickover activation and suggest that other
mechanisms of C5 cleavage and C5a generation are responsible.
HNE, a neutrophil-derived enzyme, was previously shown to
cleave C5 and, in the presence of C6, generate a C5b6-like he-
molytic complex (32). In this study, we showed that C5V802, risk
for RA, was more readily cleaved by HNE than C5I802. These
findings suggest that the observed difference in turnover between
the C5 variants lies in their susceptibility to cleavage by HNE and
perhaps other noncomplement enzymes. It is compelling that this
difference is evident even in normal individuals even though HNE
plasma levels are normally low and most are bound in an inactive
form to a1-protease inhibitor (36); however, during inflammation,
neutrophils activated locally and/or systemically release HNE
leading to markedly increased local levels (35). HNE cleaves C5
at a site close to but distinct from the C5a cleavage site [after
Arg751 in the a-chain (32)]; the precise cleavage site is not
identified. We noted that the HNE-released fragment was ∼1 kDa
larger than convertase-generated C5a (Supplemental Fig. 3); knowl-
edge that HNE preferentially cleaves after small side-chain aliphatic
amino acids with Val preferred leads us to predict that the HNE
cleavage site in C5 follows Val760, nine residues downstream of
the C5a terminus at Arg751, generating a fragment with a predicted
molecular mass of 9307 Da (921 Da larger than C5a). Efforts to
confirm this prediction by MALDI-TOF analysis are ongoing. The
HNE-generated C5a-like fragment was capable of binding C5aR
on indicator cells and triggering Ca2+ flux similar to that generated
by recombinant C5a, confirming that it was biologically active. It
is possible that this novel C5a-like molecule will be more stable
than C5a in vivo as it will not be inactivated by des-Argination.
We have shown that plasma levels of C5a and C5 are affected by
C5V802I status, likely a consequence of increased susceptibility of
the C5V802 variant to HNE cleavage. In RA, the inflamed joint is full
FIGURE 4. HNE cleaves C5 V802I variants at different rates. (A) C5
(I802 and V802) variants were incubated with HNE for 24 h. The reaction
was stopped at various time points, and samples were run on a gel (top gel)
and Western blot (bottom gel) and probed for C5a. A C5a-like molecule
appeared over time. (B) C5 (I802 and V802) variants were incubated with
HNE for 3 h. The reaction was stopped at various time points, and samples
were measured for the presence of C5a by ELISA.
FIGURE 5. Both C5 variants are functionally active when tested in
calcium flux assays. C5aR1-transfected cells were loaded with Fura-2-AM
and stimulated with C5 variants I801 (A) or V802 (B) after incubation with
HNE (solid black line) or buffer alone (not shown). Cells stimulated with
C5 not incubated with HNE were subsequently stimulated with C5a
(0.8 nM). Some cells were preincubated with C5aR antagonist (ANTA)
and then stimulated with HNE-incubated C5 (dotted line). Arrow 1, ad-
dition of C5 6 HNE; arrow 2, addition of C5a.
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of activated neutrophils and other inflammatory cells. HNE and other
proteases are abundant in RA synovial fluid (36, 37); this would lead
to local cleavage of C5 and generation of functional C5a-like frag-
ments that in turn drive more inflammation, a process that is en-
hanced for C5V802 and explains its association with inflammatory
diseases. Our findings build the case for use of HNE inhibitors in the
treatment of RA. HNE has long been implicated in chronic inflam-
matory disease (38, 39); however, although a number of effective
agents have been developed for treatment of other conditions, few
have been tested in RA. Sivelestat, a small molecule inhibitor of HNE
used in therapy of acute respiratory failure in sepsis (40), already has
proved effective in the collagen-induced arthritis model (41). The
anti-C5 mAb eculizumab was tested in RA but was not progressed;
data on the Alexion Web site shows that although the primary end
point was missed, a positive response was achieved at 3 mo in
patients stratified according to baseline TCC despite the low dose (8
mg/kg) used. Trials of the C5aR antagonist PMX53 also failed, but
this agent has failed in all trials likely because of limited bioavail-
ability (42). Our data suggest that effective inhibition of C5a/C5aR
would be therapeutic in RA.
Disclosures
C.L.H. has a contract of employment with GlaxoSmithKline, and B.P.M.
is a consultant for GlaxoSmithKline.
References
1. Silman, A. J., and M. C. Hochberg. 1993. Epidemiology of the rheumatic dis-
eases. Oxford University Press, New York, Vol. 504, p. 31‑71.
2. Tobo´n, G. J., P. Youinou, and A. Saraux. 2010. The environment, geo-
epidemiology, and autoimmune disease: Rheumatoid arthritis. J. Autoimmun.
35: 10–14.
3. Barton, A., W. Thomson, X. Ke, S. Eyre, A. Hinks, J. Bowes, D. Plant, L. J. Gibbons,
A. G. Wilson, D. E. Bax, et al. 2008. Rheumatoid arthritis susceptibility loci at
chromosomes 10p15, 12q13 and 22q13. Nat. Genet. 40: 1156–1159.
4. Kurreeman, F. A., L. Padyukov, R. B. Marques, S. J. Schrodi, M. Seddighzadeh,
G. Stoeken-Rijsbergen, A. H. van der Helm-van Mil, C. F. Allaart, W. Verduyn,
J. Houwing-Duistermaat, et al. 2007. A candidate gene approach identifies the
TRAF1/C5 region as a risk factor for rheumatoid arthritis. PLoS Med. 4: e278.
5. Thomson, W., A. Barton, X. Ke, S. Eyre, A. Hinks, J. Bowes, R. Donn,
D. Symmons, S. Hider, I. N. Bruce, et al. 2007. Rheumatoid arthritis association
at 6q23. Nat. Genet. 39: 1431–1433.
6. Stahl, E. A., S. Raychaudhuri, E. F. Remmers, G. Xie, S. Eyre, B. P. Thomson,
Y. Li, F. A. Kurreeman, A. Zhernakova, A. Hinks, et al. 2010. Genome-wide
association study meta-analysis identifies seven new rheumatoid arthritis risk
loci. Nat. Genet. 42: 508–514.
7. Morgan, B. P. 2000. The complement system: an overview. Methods Mol. Biol.
150: 1–13.
8. Walport, M. J. 2001. Complement: first of two parts. N. Engl. J. Med. 344: 1058–
1066.
9. Walport, M. J. 2001. Complement: second of two parts. N. Engl. J. Med. 344:
1140–1144.
10. Okroj, M., D. Heinega˚rd, R. Holmdahl, and A. M. Blom. 2007. Rheumatoid
arthritis and the complement system. Ann. Med. 39: 517–530.
11. Morgan, B. P., R. H. Daniels, and B. D. Williams. 1988. Measurement of ter-
minal complement complexes in rheumatoid arthritis. Clin. Exp. Immunol. 73:
473–478.
12. Hedberg, H. 1964. The depressed synovial complement activity in adult and
juvenile rheumatoid arthritis. Acta Rheumatol. Scand. 10: 109–127.
13. Kemp, P. A., J. H. Spragg, J. C. Brown, B. P. Morgan, C. A. Gunn, and
P. W. Taylor. 1992. Immunohistochemical determination of complement acti-
vation in joint tissues of patients with rheumatoid arthritis and osteoarthritis
using neoantigen-specific monoclonal antibodies. J. Clin. Lab. Immunol. 37:
147–162.
14. Wang, Y., S. A. Rollins, J. A. Madri, and L. A. Matis. 1995. Anti-C5 monoclonal
antibody therapy prevents collagen-induced arthritis and ameliorates established
disease. Proc. Natl. Acad. Sci. USA 92: 8955–8959.
15. Macor, P., P. Durigutto, L. De Maso, C. Garrovo, S. Biffi, A. Cortini, F. Fischetti,
D. Sblattero, C. Pitzalis, R. Marzari, and F. Tedesco. 2012. Treatment of ex-
perimental arthritis by targeting synovial endothelium with a neutralizing
recombinant antibody to C5. Arthritis Rheum. 64: 2559–2567.
16. Hietala, M. A., I. M. Jonsson, A. Tarkowski, S. Kleinau, and M. Pekna. 2002.
Complement deficiency ameliorates collagen-induced arthritis in mice. J.
Immunol. 169: 454–459.
17. Harris, C. L., M. Heurich, S. Rodriguez de Cordoba, and B. P. Morgan. 2012.
The complotype: dictating risk for inflammation and infection. Trends Immunol.
33: 513–521.
18. Heurich, M., R. Martı´nez-Barricarte, N. J. Francis, D. L. Roberts, S. Rodrı´guez
de Co´rdoba, B. P. Morgan, and C. L. Harris. 2011. Common polymorphisms in
C3, factor B, and factor H collaborate to determine systemic complement ac-
tivity and disease risk. Proc. Natl. Acad. Sci. USA 108: 8761–8766.
19. Kurreeman, F. A., G. N. Goulielmos, B. Z. Alizadeh, B. Rueda, J. Houwing-
Duistermaat, E. Sanchez, M. Bevova, T. R. Radstake, M. C. Vonk, E. Galanakis,
et al. 2010. The TRAF1-C5 region on chromosome 9q33 is associated with
multiple autoimmune diseases. Ann. Rheum. Dis. 69: 696–699.
20. Plenge, R. M., M. Seielstad, L. Padyukov, A. T. Lee, E. F. Remmers, B. Ding, A. Liew,
H. Khalili, A. Chandrasekaran, L. R. Davies, et al. 2007. TRAF1-C5 as a risk locus for
rheumatoid arthritis—a genomewide study. N. Engl. J. Med. 357: 1199–1209.
21. Chai, L., Y. Q. Song, K. Y. Zee, and W. K. Leung. 2010. Single nucleotide
polymorphisms of complement component 5 and periodontitis. J. Periodontal
Res. 45: 301–308.
22. Woehrl, B., M. C. Brouwer, C. Murr, S. G. Heckenberg, F. Baas, H. W. Pfister,
A. H. Zwinderman, B. P. Morgan, S. R. Barnum, A. van der Ende, et al. 2011.
Complement component 5 contributes to poor disease outcome in humans and
mice with pneumococcal meningitis. J. Clin. Invest. 121: 3943–3953.
23. Hoke, M., W. Speidl, M. Schillinger, E. Minar, S. Zehetmayer, M. Scho¨nherr,
O. Wagner, and C. Mannhalter. 2012. Polymorphism of the complement 5 gene and
cardiovascular outcome in patients with atherosclerosis. Eur. J. Clin. Invest. 42: 921–926.
24. Greisenegger, S., S. Zehetmayer, P. Bauer, G. Endler, J. Ferrari, W. Lang,
M. Janisiw, L. Steiner, S. Cheng, W. Lalouschek, and C. Mannhalter. 2009.
Polymorphisms in inflammatory genes and the risk of ischemic stroke and
transient ischemic attack: results of a multilocus genotyping assay. Clin. Chem.
55: 134–138.
25. Aletaha, D., T. Neogi, A. J. Silman, J. Funovits, D. T. Felson, C. O. Bingham, III,
N. S. Birnbaum, G. R. Burmester, V. P. Bykerk, M. D. Cohen, et al. 2010. 2010
Rheumatoid arthritis classification criteria: an American College of Rheumatology/
European League Against Rheumatism collaborative initiative. Arthritis Rheum.
62: 2569–2581.
26. Harris, C. L., A. S. Williams, S. M. Linton, and B. P. Morgan. 2002. Coupling
complement regulators to immunoglobulin domains generates effective anti-
complement reagents with extended half-life in vivo. Clin. Exp. Immunol. 129:
198–207.
27. Tortajada, A., T. Montes, R. Martı´nez-Barricarte, B. P. Morgan, C. L. Harris, and
S. R. de Co´rdoba. 2009. The disease-protective complement factor H allotypic
variant Ile62 shows increased binding affinity for C3b and enhanced cofactor
activity. Hum. Mol. Genet. 18: 3452–3461.
28. Montes, T., A. Tortajada, B. P. Morgan, S. Rodrı´guez de Co´rdoba, and
C. L. Harris. 2009. Functional basis of protection against age-related macular
degeneration conferred by a common polymorphism in complement factor B.
Proc. Natl. Acad. Sci. USA 106: 4366–4371.
29. Fu, Q., P. McPhie, and D. C. Gowda. 1998. Methionine modification impairs the
C5-cleavage function of cobra venom factor-dependent C3/C5 convertase. Bio-
chem. Mol. Biol. Int. 45: 133–144.
30. van den Berg, C. W., R. M. Gonc¸alves-de-Andrade, C. K. Okamoto, and
D. V. Tambourgi. 2012. C5a receptor is cleaved by metalloproteases induced by
sphingomyelinase D from Loxosceles spider venom. Immunobiology 217: 935–941.
31. Al-Mohanna, F. A., and M. B. Hallett. 1988. The use of fura-2 to determine the
relationship between cytoplasmic free Ca2+ and oxidase activation in rat neu-
trophils. Cell Calcium 9: 17–26.
32. Vogt, W. 2000. Cleavage of the fifth component of complement and generation
of a functionally active C5b6-like complex by human leukocyte elastase.
Immunobiology 201: 470–477.
33. Pangburn, M. K., and N. Rawal. 2002. Structure and function of complement C5
convertase enzymes. Biochem. Soc. Trans. 30: 1006–1010.
34. Hadders, M. A., D. Bubeck, P. Roversi, S. Hakobyan, F. Forneris, B. P. Morgan,
M. K. Pangburn, O. Llorca, S. M. Lea, and P. Gros. 2012. Assembly and reg-
ulation of the membrane attack complex based on structures of C5b6 and sC5b9.
Cell Reports 1: 200–207.
35. Mikes, B., G. Sinkovits, P. Farkas, D. Csuka, A. Schlammadinger, K. Ra´zso´,
J. Demeter, G. Domja´n, M. Re´ti, and Z. Proha´szka. 2014. Elevated plasma
neutrophil elastase concentration is associated with disease activity in patients
with thrombotic thrombocytopenic purpura. Thromb. Res. 133: 616–621.
36. Nakano, S., T. Ikata, I. Kinoshita, J. Kanematsu, and S. Yasuoka. 1999. Char-
acteristics of the protease activity in synovial fluid from patients with rheumatoid
arthritis and osteoarthritis. Clin. Exp. Rheumatol. 17: 161–170.
37. Bazzichi, L., M. L. Ciompi, L. Betti, A. Rossi, D. Melchiorre, M. Fiorini,
G. Giannaccini, and A. Lucacchini. 2002. Impaired glutathione reductase ac-
tivity and levels of collagenase and elastase in synovial fluid in rheumatoid ar-
thritis. Clin. Exp. Rheumatol. 20: 761–766.
38. Do¨ring, G. 1994. The role of neutrophil elastase in chronic inflammation. Am. J.
Respir. Crit. Care Med. 150: S114–S117.
39. Tremblay, G. M., M. F. Janelle, and Y. Bourbonnais. 2003. Anti-inflammatory
activity of neutrophil elastase inhibitors. Curr. Opin. Investig. Drugs 4: 556–565.
40. Miyoshi, S., H. Hamada, R. Ito, H. Katayama, K. Irifune, T. Suwaki,
N. Nakanishi, T. Kanematsu, K. Dote, M. Aibiki, et al. 2013. Usefulness of
a selective neutrophil elastase inhibitor, sivelestat, in acute lung injury patients
with sepsis. Drug Des Devel Ther 7: 305–316.
41. Kakimoto, K., A. Matsukawa, M. Yoshinaga, and H. Nakamura. 1995. Sup-
pressive effect of a neutrophil elastase inhibitor on the development of collagen-
induced arthritis. Cell. Immunol. 165: 26–32.
42. Morgan, M., A. C. Bulmer, T. M. Woodruff, L. M. Proctor, H. M. Williams,
S. Z. Stocks, S. Pollitt, S. M. Taylor, and I. A. Shiels. 2008. Pharmacokinetics of
a C5a receptor antagonist in the rat after different sites of enteral administration.
Eur. J. Pharm. Sci. 33: 390–398.
3034 ANALYSIS OF AN SNP LINKED TO RA
 at Cardiff U
niv on M
arch 27, 2015
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
